Sacubitril-Valsartan

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

41 API Suppliers, 17 USDMF, 6 EU WC, 13 KDMF, 10 NDC API, 30 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

INTERMEDIATES

9 Suppliers

9 Suppliers

DOSSIERs // Finished Dosage Formulations

6 Dossiers, 6 Listed Dossiers

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

2 US Medicaid Prescriptions

MARKET PLACE

13 APIs

13 APIs

DIGITAL CONTENT

2 Data Compilations & Company Tracker #PharmaFlow, 40 News, 1 Monthly Stock Recap #PipelineProspector

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

2,442

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

2,926.00

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Sacubitril valsartan sodium hydrate, Sacubitril mixture with valsartan, Wb8ft61183, Lcz 696, Sacubitril valsartan sodium hydrate (jan), Sacubitril valsartan sodium hydrate [jan]

Molecular Formula

C₉₆H₁₂₀N₁₂Na₆O₂₁

Molecular Weight

1916.0 g/mol

InChI Key

ZASXKEGREHRXDL-CAWNUZPDSA-H

FDA UNII

WB8FT61183

Sacubitril/Valsartan is a combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.

1 2D Structure

Sacubitril-Valsartan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate

2.1.2 InChI

InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1

2.1.3 InChI Key

ZASXKEGREHRXDL-CAWNUZPDSA-H

2.1.4 Canonical SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

2.1.5 Isomeric SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

2.2 Other Identifiers

2.2.1 UNII

WB8FT61183

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate

2. Lcz 696

3. Lcz-696

4. Lcz696

5. Sacubitril And Valsartan Drug Combination

6. Sacubitril And Valsartan Sodium Anhydrous Drug Combination

7. Sacubitril And Valsartan Sodium Hydrate Drug Combination

8. Sacubitril Valsartan Drug Combination

9. Sacubitril Valsartan Sodium Anhydrous

10. Sacubitril Valsartan Sodium Hydrate

11. Sacubitril-valsartan

12. Sacubitril-valsartan Sodium Anhydrous Drug Combination

13. Sacubitril-valsartan Sodium Hydrate Drug Combination

14. Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) Hemipentahydrate

2.3.2 Depositor-Supplied Synonyms

1. Sacubitril Valsartan Sodium Hydrate

2. Sacubitril Mixture With Valsartan

3. Wb8ft61183

4. Lcz 696

5. Sacubitril Valsartan Sodium Hydrate (jan)

6. Sacubitril Valsartan Sodium Hydrate [jan]

7. Entresto (tn)

8. Unii-wb8ft61183

9. Valsartan Mixture With Ahu-377

10. Ex-a2849

11. Mfcd29477717

12. 3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate

13. Ac-29037

14. Sucabitril Valsartan Sodium Hydrate

15. Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) Hemipentahydrate

16. D10226

17. Valsartan Ahu-377 Sodium Hemipentahydrate

18. Q27292546

19. L-valine, N-(1-oxopentyl)-n-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Compd. With .alpha.-ethyl (.alpha.r,.gamma.s)-.gamma.-((3-carboxy-1-oxopropyl)amino)-.alpha.-methyl(1,1'-biphenyl)-4-pentanoate, Sodium Salt, Hydrate (2:2:6:5)

20. L-valine, N-(1-oxopentyl)-n-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Compd. With Alpha-ethyl(alphar,gammas)-gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl(1,1'-biphenyl)-4-pentanoate, Sodium Salt, Hydrate (2:2:6:5)

2.4 Create Date

2013-05-27

3 Chemical and Physical Properties

Molecular Formula	C₉₆H₁₂₀N₁₂Na₆O₂₁
Molecular Weight	1916.0 g/mol
Hydrogen Bond Donor Count	7
Hydrogen Bond Acceptor Count	29
Rotatable Bond Count	40
Exact Mass	1915.8110694 g/mol
Monoisotopic Mass	1914.8077146 g/mol
Topological Polar Surface Area	396 Å²
Heavy Atom Count	135
Formal Charge	0
Complexity	1140
Isotope Atom Count	0
Defined Atom Stereocenter Count	6
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	15

4 Drug and Medication Information

4.1 Drug Indication

Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Angiotensin Receptor Antagonists

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. (See all compounds classified as Angiotensin Receptor Antagonists.)

5.2 ATC Code

C09DX04